[1]李智强,陈从其,陈锦添,等.基于TCGA数据库探讨BEND5表达对膀胱癌患者生存及癌细胞迁移能力的影响[J].福建医药杂志,2025,47(07):1-5.[doi:10.20148/j.fmj.2025.07.001]
　LI Zhiqiang,CHEN Congqi,CHEN Jintian,et al.Impact of BEND5 expression on survival of bladder cancer patients and migration ability of bladder cancer cells based on TCGA database[J].FUJIAN MEDICAL JOURNAL,2025,47(07):1-5.[doi:10.20148/j.fmj.2025.07.001]
点击复制

基于TCGA数据库探讨BEND5表达对膀胱癌患者生存及癌细胞迁移能力的影响()
分享到：

《福建医药杂志》[ISSN:1002-2600/CN:35-1071/R]

卷:
47
期数:
2025年07期
页码:
1-5
栏目:
临床研究
出版日期:
2025-07-20

文章信息/Info

Title:
Impact of BEND5 expression on survival of bladder cancer patients and migration ability of bladder cancer cells based on TCGA database
文章编号:
1002-2600(2025)07-0001-05
作者:
李智强1; 陈从其1; 陈锦添1; 陈伟2; 董菲艳3; 周素娟4; 林云侨1
1 宁德师范学院附属宁德市医院泌尿外科,宁德 352100; 2 宁德师范学院附属宁德市医院疼痛医学科,宁德 352100; 3 宁德师范学院附属宁德市医院儿科,宁德 352100; 4 宁德师范学院附属宁德市医院病理科,宁德 352100
Author(s):
LI Zhiqiang1;  CHEN Congqi1;  CHEN Jintian1;  CHEN Wei2;  DONG Feiyan3;  ZHOU Sujuan4;  LIN Yunqiao1
1 Department of Urology, Ningde Municipal Hospital of Ningde Normal University, Ningde, Fujian 352100, China; 2 Department of Pain Medicine, Ningde Municipal Hospital of Ningde Normal University, Ningde, Fujian 352100, China; 3 Department of Pediatrics, Ningde Municipal Hospital of Ningde Normal University, Ningde, Fujian 352100, China; 4 Department of Pathology, Ningde Municipal Hospital of Ningde Normal University, Ningde, Fujian 352100, China
关键词:
膀胱癌;  BEND5;  抗癌;  mTOR通路;  TCGA数据库
Keywords:
bladder cancer;  BEND5;  anticancer;  mTOR pathway;  TCGA database
分类号:
R737.14
DOI:
10.20148/j.fmj.2025.07.001
文献标志码:
B
摘要:
目的 探讨膀胱癌组织与癌旁组织中BEN结构域蛋白5(BEND5)表达差异及BEND5对膀胱癌细胞迁移能力和雷帕霉素靶蛋白(mTOR)通路的影响。方法 利用癌症基因组图集(TCGA)数据库分析BEND5表达与膀胱癌患者生存的关系; 收集40例膀胱癌患者的癌及癌旁组织,采用荧光定量PCR(qPCR)及蛋白免疫印迹法(Western blot, WB)检测BEND5 mRNA及蛋白表达差异; 膀胱癌5637和UMUC3细胞转染BEND5-siRNA后,划痕-愈合实验检测迁移能力的差异,WB法检测mTOR通路蛋白及波形蛋白(Vimentin)表达差异。结果 通过TCGA分析发现,在膀胱癌中BEND5表达下调,且低表达的膀胱癌患者生存率更低。实验显示膀胱癌组织中BEND5 mRNA和蛋白表达均低于癌旁组织; 沉默BEND5提高了膀胱癌细胞的迁移能力,并上调mTOR通路蛋白及波形蛋白表达。结论 在膀胱癌组织中BEND5基因低表达,可能通过激活mTOR通路及促进癌细胞迁移的方式降低患者的生存率。
Abstract:
Objective To explore the differential expression of BEND5 in bladder cancer tissues compared to normal tissues and the impact of BEND5 on the migration ability of bladder cancer cells and the mTOR pathway. Methods TCGA database was used to analyze the differences in BEND5 expression and survival of patients with bladder cancer. The mRNA and protein expression of BEND5 were detected by quantitative real-time PCR(qPCR)and Western blot(WB)in 40 bladder cancer patients from Ningde Municipal Hospital of Ningde Normal University. After transfection of bladder cancer 5637 and UMUC3 cells with BEND5-siRNA, scratch-healing assays were performed to assess the migration ability of bladder cancer cells. WB was used to examine the expression of mTOR pathway protein and Vimentin in different groups of bladder cancer cells. Results Analysis of the TCGA database revealed that BEND5 was significantly downregulated in bladder cancer tissues, and patients with low expression of BEND5 had a lower survival rate. And our study confirmed lower mRNA and protein expression of BEND5 in cancer tissues than in adjacent tissues. Silencing BEND5 expression in bladder cancers cells could improve their migration ability and significantly increase the expression of mTOR pathway protein and Vimentin. Conclusion Significantly low expression of BEND5 in bladder cancer may reduce survival rate by activating the mTOR pathway and promoting the migration of cancer cells.

参考文献/References:

[1] 李辉章, 郑荣寿, 杜灵彬, 等. 中国膀胱癌流行现状与趋势分析[J]. 中华肿瘤杂志, 2021, 43(3): 293-298.
[2] Luo L S, Luan H H, Zhang P, et al. The disease burden of bladder cancer and its attributable risk factors in five Eastern Asian countries, 1990-2019: a population-based comparative study[J]. BMC public health, 2024, 24(1): 2404.
[3] Jenkins R W, Barbie D A, Flaherty K T. Mechanisms of resistance to immune checkpoint inhibitors[J]. British journal of cancer, 2018, 118(1): 9-16.
[4] Bednova O, Leyton J V. Targeted Molecular Therapeutics for bladder cancer-a new option beyond the mixed fortunes of immune checkpoint inhibitors?[J]. International journal of molecular sciences, 2020, 21(19): 7268.
[5] Lin R K, Hung W Y, Huang Y F, et al. Hypermethylation of BEND5 contributes to cell proliferation and is a prognostic marker of colorectal cancer[J]. Oncotarget, 2017, 8(69): 113431-113443.
[6] Shi Y, Zhang D, Chen J, et al. Interaction between BEND5 and RBPJ suppresses breast cancer growth and metastasis via inhibiting Notch signaling[J]. International journal of biological sciences, 2022, 18(10): 4233-4244.
[7] Ma Y, Wu L. Investigation of the function of the novel tumor marker BEND5 in lung adenocarcinoma based on data mining and in vitro analysis[J]. Journal of thoracic disease, 2023, 15(4): 1749-1769.
[8] Liu G Y, Sabatini D M. mTOR at the nexus of nutrition, growth, ageing and disease[J]. Nature reviews molecular cell biology, 2020, 21(4): 183-203.
[9] Mossmann D, Park S, Hall M N. mTOR signalling and cellular metabolism are mutual determinants in cancer[J]. Nature reviews cancer, 2018, 18(12): 744-757.
[10] Hua H, Kong Q, Zhang H, et al. Targeting mTOR for cancer therapy[J]. Journal of hematology & oncology, 2019, 12: 71.
[11] 曾繁浩, 雷容, 张克, 等. mTOR在膀胱癌治疗中的研究进展[J]. 医学综述, 2021, 27(8): 1523-1527,1533.
[12]郑荣寿,陈茹,韩冰峰,等.2022年中国恶性肿瘤流行情况分析[J]. 中华肿瘤杂志, 2024, 46(3): 221-231.
[13] Dai Q, Ren A, Westholm J O, et al. Common and distinct DNA-binding and regulatory activities of the BEN-solo transcription factor family[J]. Genes & Development, 2015, 29(1): 48-62.
[14] Huan J, Grivas P, Birch J, Hansel D E, et al. Emerging roles for mammalian target of rapamycin(mtor)complexes in bladder cancer progression and therapy[J]. Cancers, 2022, 14(6):1555.
[15] Blume-Jensen P, Hunter T. Oncogenic kinase signalling[J]. Nature, 2001, 411(6835): 355-365.
[16] 陈康, 邢基, 张云龙, 等. PI3K/AKT/mTOR通路抑制剂在膀胱癌中的研究进展[J]. 现代肿瘤医学, 2023, 31(3): 575-579.
[17] Polacheck W J, Zervantonakis I K, Kamm R D. Tumor cell migration in complex microenvironments[J]. Cellular and molecular life sciences: CMLS, 2013, 70(8): 1335-1356.
[18] Zhu Q S, Rosenblatt K, Huang K L, et al. Vimentin is a novel AKT1 target mediating motility and invasion[J]. Oncogene, 2011, 30(4): 457-470.
[19] Mittal V. Epithelial mesenchymal transition in tumor metastasis[J]. Annual review of pathology, 2018, 13: 395-412.

相似文献/References:

[1]方潇,戴天增,池哲子,等.良性前列腺增生和男性群体膀胱癌的因果效应:双样本孟德尔随机化研究[J].福建医药杂志,2024,46(06):1.[doi:10.20148/j.fmj.2024.06.001]
　FANG Xiao,DAI Tianzeng,CHI Zhezi,et al.Causal effects of benign prostatic hyperplasia and bladder cancer in male population: a two-sample Mendelian randomization study[J].FUJIAN MEDICAL JOURNAL,2024,46(07):1.[doi:10.20148/j.fmj.2024.06.001]

备注/Memo

备注/Memo:
基金项目:福建省自然科学基金项目(2021J011160); 宁德师范学院创新团队(2023T08)
通信作者:林云侨,Email: 12306184@qq.com
更新日期/Last Update: 2025-07-20